Zarnowski Tomasz

Stalmans Ingeborg, Lim Kin Sheng, Oddone Francesco, Fichtl Marek, Belda Jose I, Hommer Anton et al.

This study found netarsudil/latanoprost was non-inferior to bimatoprost/timolol in lowering IOP for glaucoma/ocular hypertension. It offers an effective alternative fixed-dose combination, though with different side effect profiles.

Tun Tin A, Sawicki Andrzej, Wilkos-Kuc Agnieszka, Aung Tin, Zarnowski Tomasz

This study found LPI-induced angle widening varies by angle closure mechanism, with thick peripheral irises showing less widening despite greater iris curvature reduction, guiding personalized treatment.

Tun Tin A, Sawicki Andrzej, Wilkos-Kuc Agnieszka, Aung Tin, Zarnowski Tomasz

Laser iridotomy widened the angle and flattened the iris circumferentially in Caucasian eyes. Baseline refractive error, lens vault, and iris volume predict the extent of this angle widening.

Zarnowski Tomasz, Harasymowycz Paul

Jurkowska-Dudzińska Justyna, Kosior-Jarecka Ewa, Zarnowski Tomasz

This study compared 5-FU and bevacizumab as trabeculectomy adjuvants. Both achieved similar 1-year IOP reduction, but bevacizumab patients required more additional medication for control.

Zarnowski Tomasz, Kosior-Jarecka Ewa

Thaler Sebastian, Choragiewicz Tomasz J, Rejdak Robert, Fiedorowicz Michal, Turski Waldemar A, Tulidowicz-Bielak Maria et al.

Ketone bodies (ACA/BHB) protected rat retinal ganglion cells from NMDA-induced damage, potentially by modulating kynurenic acid. This suggests ketone bodies could be a future neuroprotective glaucoma treatment.

Nowomiejska Katarzyna, Rejdak Robert, Zagorski Zbigniew, Zarnowski Tomasz

This study compared SAP and SKP in ONHD patients, finding both methods are needed to fully characterize diverse visual field defects, as each detects unique abnormalities.